Preventable kidney failure: The cost of diabetes neglect?

New Zealand Medical Journal

Volumn 119, Issue 1246, 2006, Pages

  Endre, Zoltán H ^a,b   Beaven, Don ^a   Buttimore, Adrian ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; BEHAVIOR MODIFICATION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIALYSIS; DRUG COST; DRUG MEGADOSE; EARLY DIAGNOSIS; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LENGTH OF STAY; LIFESTYLE; NEW ZEALAND; REGISTRATION; CHRONIC KIDNEY FAILURE; ECONOMICS; PREVALENCE; REGISTER; RENAL REPLACEMENT THERAPY; STATISTICS;

DIABETIC NEPHROPATHIES; HOSPITALIZATION; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LENGTH OF STAY; NEW ZEALAND; PREVALENCE; REGISTRIES; RENAL DIALYSIS;

EID: 33845381324     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Zimmet P. The burden of type 2 diabetes: are we doing enough? Diabetes Metab. 2003;29(4 Pt 2):6S9-18.
2. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-53.
3. Scragg R. Preventing diabetes-time is running out. N Z Med J 2004;117(1207). URL: http://www.nzma.org.nz/journal/117-1207/1220
4. PricewaterhouseCoopers. Type 2 Diabetes: managing for better health outcomes. Wellington: Commissioned by Diabetes NZ Inc; 2001. URL: http://www.diabetes.org.nz/resources/pwcreport.html
5. New Zealand Guidelines Group. Management of type 2 diabetes. Wellington: NZGG; 2003. URL: http://www.nzgg.org.nz/guidelines/ dsp_guideline_popup.cfm?guidelineID=36
6. Health Canada health information backgrounder: Canadian Diabetes Strategy. 2001. URL: http://www.hc-sc.gc.ca/ahc-asc/activit/strateg/ diabete/index_e.html
7. Local Diabetes Team Canterbury. Annual report for 2004. Christchurch; 2005: http://www.cdhb.govt.nz/planning/documents/ Annual%20Report%202004%20March05.pdf
8. Olveira-Fuster G, Olvera-Marquez P, Carral-Sanlaureano F, et al. Excess hospitalizations, hospital days, and inpatient costs among people with diabetes in Andalusia, Spain. Diabetes Care. 2004;27:1904-9.
9. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2004;27(90001):5S-10.
10. Canadian Diabetes Advisory Board. Diabetes in Canada: strategies toward 2000. Canadian Diabetes Association; 2000.
11. O'Brien JA, Patrick AR, Caro JJ. Cost of managing complications resulting from type 2 diabetes mellitus in Canada. BMC Health Serv Res. 2003;3:7.
12. Gordois A, Scuffham P, Shearer A, Oglesby A. The health care costs of diabetic nephropathy in the United States and the United Kingdom. J Diabetes Complications. 2004;18(1):18-26.
13. ANZDATA Registry Report 2005. Adelaide, South Australia; 2005. URL: http://www.anzdata.org.au/
14. Collins J, Hotu C, Bagg W, et al. Delay future end stage nephropathy due to diabetes (DEFEND) In: ANZSN Annual Scientific Meeting Wellington, New Zealand; 2005. http://www.blackwell-synergy.com/doi/pdf/10.1111/ j.1440-1797.2005.00461.x
15. Counties Manukau District Health Board. Let's Beat Diabetes - a catalyst for change; 2005. http://www.letsbeatdiabetes.org.nz/page/diabetes_16.php
16. Waikato District Health Board. Te Wai o Rona: Diabetes Prevention Strategy; 2004. URL: http://www.waikatodhb.govt.nz/wdhb/default.asp
17. Crampton P, Perera R, Crengle S, et al. What makes a good performance indicator? Devising primary care performance indicators for New Zealand. N Z Med J. 2004;117(1191). URL: http://www.nzma.org.nz/journal/117-1191/ 820
18. Beaven DW, Dear M, Thomson S. Performance indicators: primary health, secondary care, and diabetes [letter]. N Z Med J. 2004;117(1203). URL: http://www.nzma.org.nz/journal/117-1203/1109
19. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456-62.
20. Hebert LA, Bain RP, Verme D, et al. Remission of nephrotic range proteinuria in type I diabetes. Collaborative Study Group. Kidney Int. 1994;46:1688-93.
21. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-8.
22. Lewis EJ. The role of angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2 diabetes. Am J Hypertens. 2002;15:123S-8S.
23. Melville A, Richardson R, Lister-Sharp D, McIntosh A. Complications of diabetes: renal disease and promotion of self-management. Qual Health Care. 2000;9:257-63.
24. Winocour PH. Effective diabetes care: a need for realistic targets. BMJ. 2002;324:1577-80.
25. Marshall SM. Recent advances in diabetic nephropathy. Clin Med. 2004;4:277-82.
26. Chen F, Florkowski CM, Dever M, Beaven DW. Death certification and New Zealand Health Information Service (NZHIS) statistics for diabetes mellitus: an under-recognised health problem. Diabetes Res Clin Pract. 2004;63:113-8.
27. Brown JB, Pedula KL, Bakst AW. The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med. 1999;159:1873-80.
28. Manley HJ, Cannella CA. Nondialysis (home) medication utilization and cost in diabetic and nondiabetic hemodialysis patients. Nephrol News Issues. 2005;19:27-8.
29. Johnson DW. Evidence-based guide to slowing the progression of early renal insufficiency. Intern Med J. 2004;34:50-7.
30. Ritz E, Dikow R. Hypertension and antihypertensive treatment of diabetic nephropathy. Nat Clin Pract Nephrol.2006;2:562-7.
31. Mann JI, Tipene-Leach DC, Pahau HL, et al. Insulin resistance and impaired glucose metabolism in a predominantly Maori community. Diabetes Res Clin Pract. 2006;72:68-74. Epub 2005 Sep 27.